Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology

JAMA. 2016 Oct 18;316(15):1541-1542. doi: 10.1001/jama.2016.12770.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Bevacizumab / therapeutic use
  • Centers for Medicare and Medicaid Services, U.S. / standards*
  • Cetuximab / therapeutic use
  • Erlotinib Hydrochloride / therapeutic use*
  • Formularies as Topic / standards*
  • Humans
  • Medical Oncology / standards*
  • Neoplasms / drug therapy*
  • Off-Label Use / standards*
  • Protein Kinase Inhibitors / therapeutic use*
  • Review Literature as Topic
  • United States

Substances

  • Protein Kinase Inhibitors
  • Bevacizumab
  • Erlotinib Hydrochloride
  • Cetuximab